At present, the National Institute for Health and Care Excellence (NICE) recommends the use of ODX testing to guide the decision-making on chemotherapy after surgery in ER-positive, HER2-negative and lymph node-negative early breast cancer patients [18]. This evidence concerns the gene ERBB2 and breast carcinoma.